联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 6089人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313664, encodeId=5808131366416, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, objectType=article, longId=101423, objectId=a07f101423fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a07f101423fa, replyNumber=0, likeNumber=0, createdTime=2017-06-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a07f101423fa, moduleTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a07f101423fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313663, encodeId=42f21313663f0, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ADV FUNCT MATER：多功能纳米诊疗平台，双模态成像导航下的肿瘤联合治疗, objectType=article, longId=100206, objectId=71b610020698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71b610020698, replyNumber=0, likeNumber=76, createdTime=2017-06-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71b610020698, moduleTitle=ADV FUNCT MATER：多功能纳米诊疗平台，双模态成像导航下的肿瘤联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71b610020698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313662, encodeId=3c9313136624c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Adv Mater：黑磷纳米药物运输体系，多模式联合治疗癌症, objectType=article, longId=100047, objectId=92b410004e13, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92b410004e13, replyNumber=0, likeNumber=84, createdTime=2017-05-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92b410004e13, moduleTitle=Adv Mater：黑磷纳米药物运输体系，多模式联合治疗癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92b410004e13)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313865, encodeId=8ef0131386548, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAMA Psychiatry：抗精神病药物联合治疗效果荟萃分析, objectType=article, longId=99112, objectId=a27e9911236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a27e9911236, replyNumber=0, likeNumber=121, createdTime=2017-05-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a27e9911236, moduleTitle=JAMA Psychiatry：抗精神病药物联合治疗效果荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a27e9911236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313661, encodeId=0156131366134, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Obes Metab：对于亚洲2型糖尿病患者这种药物联合治疗安全有效, objectType=article, longId=98965, objectId=15f2989655e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15f2989655e, replyNumber=0, likeNumber=0, createdTime=2017-05-19, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15f2989655e, moduleTitle=Diabetes Obes Metab：对于亚洲2型糖尿病患者这种药物联合治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15f2989655e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313660, encodeId=24f1131366010, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Br J Anaesth：预防儿童术后恶心呕吐的联合治疗方案, objectType=article, longId=98836, objectId=e56b98836d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56b98836d1, replyNumber=0, likeNumber=74, createdTime=2017-05-17, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56b98836d1, moduleTitle=Br J Anaesth：预防儿童术后恶心呕吐的联合治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56b98836d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313659, encodeId=b4fa1313659aa, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ANN RHEUM DIS：甲氨蝶呤与每日10mg泼尼松联合治疗早期类风湿关节炎更有效, objectType=article, longId=97430, objectId=4a879e430d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a879e430d0, replyNumber=0, likeNumber=93, createdTime=2017-04-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a879e430d0, moduleTitle=ANN RHEUM DIS：甲氨蝶呤与每日10mg泼尼松联合治疗早期类风湿关节炎更有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a879e430d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313658, encodeId=bd8113136583c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet Infect Dis：产碳青霉烯酶肠杆菌血液感染的联合治疗, objectType=article, longId=96879, objectId=f530968e9d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f530968e9d8, replyNumber=0, likeNumber=96, createdTime=2017-04-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f530968e9d8, moduleTitle=Lancet Infect Dis：产碳青霉烯酶肠杆菌血液感染的联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f530968e9d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313657, encodeId=3299131365e8e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Plos One：Cherlerythrine与厄洛替尼联合治疗对非小细胞肺癌的作用如何？, objectType=article, longId=95901, objectId=f73e9590141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f73e9590141, replyNumber=0, likeNumber=109, createdTime=2017-04-16, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f73e9590141, moduleTitle=Plos One：Cherlerythrine与厄洛替尼联合治疗对非小细胞肺癌的作用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f73e9590141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313656, encodeId=2f3e13136565d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ACCR年会：HER2靶向联合治疗对接受大量前期治疗的HER2阳性结直肠癌患者有效, objectType=article, longId=94574, objectId=4a4f945e447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4f945e447, replyNumber=0, likeNumber=72, createdTime=2017-04-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4f945e447, moduleTitle=ACCR年会：HER2靶向联合治疗对接受大量前期治疗的HER2阳性结直肠癌患者有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4f945e447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313655, encodeId=1f2313136554c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Care：胰岛素和胰高血糖素样肽1受体激动剂联合治疗2型糖尿病！, objectType=article, longId=93430, objectId=5ed393430f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ed393430f3, replyNumber=0, likeNumber=76, createdTime=2017-03-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ed393430f3, moduleTitle=Diabetes Care：胰岛素和胰高血糖素样肽1受体激动剂联合治疗2型糖尿病！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ed393430f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313654, encodeId=b097131365457, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Stroke：脑卒中患者运用依达拉奉和组织型纤溶酶原激活剂联合治疗的疗效分析！, objectType=article, longId=88073, objectId=2a78880e3f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a78880e3f3, replyNumber=0, likeNumber=81, createdTime=2017-01-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a78880e3f3, moduleTitle=Stroke：脑卒中患者运用依达拉奉和组织型纤溶酶原激活剂联合治疗的疗效分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a78880e3f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313653, encodeId=7f361313653ef, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Br J Surg：PTA、SEP和联合治疗下肢跛行, objectType=article, longId=80888, objectId=0d5f8088847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d5f8088847, replyNumber=0, likeNumber=68, createdTime=2016-10-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d5f8088847, moduleTitle=Br J Surg：PTA、SEP和联合治疗下肢跛行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d5f8088847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313652, encodeId=dfab13136529b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Care：依帕列净+二甲双胍联合治疗2型糖尿病, objectType=article, longId=77896, objectId=8445e78962a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8445e78962a, replyNumber=0, likeNumber=79, createdTime=2016-09-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8445e78962a, moduleTitle=Diabetes Care：依帕列净+二甲双胍联合治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8445e78962a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313651, encodeId=59bb131365196, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：Daratumumab、硼替佐米和地塞米松联合治疗多发性骨髓瘤效果更好, objectType=article, longId=75866, objectId=d615e58662b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d615e58662b, replyNumber=0, likeNumber=83, createdTime=2016-08-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d615e58662b, moduleTitle=NEJM：Daratumumab、硼替佐米和地塞米松联合治疗多发性骨髓瘤效果更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d615e58662b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313650, encodeId=422113136509e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), objectType=article, longId=71408, objectId=4379e1408e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4379e1408e0, replyNumber=0, likeNumber=38, createdTime=2016-06-23, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4379e1408e0, moduleTitle=ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4379e1408e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313649, encodeId=50321313649ca, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=艾辉胜教授：微移植和CAR-T联合治疗研究, objectType=article, longId=71318, objectId=bdcfe131825, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdcfe131825, replyNumber=0, likeNumber=71, createdTime=2016-06-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdcfe131825, moduleTitle=艾辉胜教授：微移植和CAR-T联合治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdcfe131825)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313648, encodeId=443c13136483f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌, objectType=article, longId=68497, objectId=52236849e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52236849e07, replyNumber=0, likeNumber=88, createdTime=2016-05-19, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52236849e07, moduleTitle=FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52236849e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313647, encodeId=2aef131364e9d, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=肿瘤免疫疗法下一波浪潮！联合治疗, objectType=article, longId=67577, objectId=75ec6e57781, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75ec6e57781, replyNumber=0, likeNumber=85, createdTime=2016-05-07, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75ec6e57781, moduleTitle=肿瘤免疫疗法下一波浪潮！联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75ec6e57781)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313646, encodeId=ac271313646ea, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=CHEST：言语治疗和普瑞巴林联合治疗慢性顽固性咳嗽更优, objectType=article, longId=64593, objectId=005c6459354, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005c6459354, replyNumber=0, likeNumber=77, createdTime=2016-03-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005c6459354, moduleTitle=CHEST：言语治疗和普瑞巴林联合治疗慢性顽固性咳嗽更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005c6459354)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？

2017-06-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ADV FUNCT MATER：多功能纳米诊疗平台，双模态成像导航下的肿瘤联合治疗

2017-06-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Adv Mater：黑磷纳米药物运输体系，多模式联合治疗癌症

2017-05-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAMA Psychiatry：抗精神病药物联合治疗效果荟萃分析

2017-05-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Obes Metab：对于亚洲2型糖尿病患者这种药物联合治疗安全有效

2017-05-19

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Br J Anaesth：预防儿童术后恶心呕吐的联合治疗方案

2017-05-17

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ANN RHEUM DIS：甲氨蝶呤与每日10mg泼尼松联合治疗早期类风湿关节炎更有效

2017-04-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet Infect Dis：产碳青霉烯酶肠杆菌血液感染的联合治疗

2017-04-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Plos One：Cherlerythrine与厄洛替尼联合治疗对非小细胞肺癌的作用如何？

2017-04-16

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ACCR年会：HER2靶向联合治疗对接受大量前期治疗的HER2阳性结直肠癌患者有效

2017-04-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Care：胰岛素和胰高血糖素样肽1受体激动剂联合治疗2型糖尿病！

2017-03-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Stroke：脑卒中患者运用依达拉奉和组织型纤溶酶原激活剂联合治疗的疗效分析！

2017-01-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Br J Surg：PTA、SEP和联合治疗下肢跛行

2016-10-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Care：依帕列净+二甲双胍联合治疗2型糖尿病

2016-09-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：Daratumumab、硼替佐米和地塞米松联合治疗多发性骨髓瘤效果更好

2016-08-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ASCO 2016：pembrolizumab和ipilimumab联合治疗晚期黑色素瘤的安全性和有效性在可接受范围(KEYNOTE-029)

2016-06-23

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

艾辉胜教授：微移植和CAR-T联合治疗研究

2016-06-22

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

FDA批准Lenvatinib+依维莫司联合治疗晚期肾癌

2016-05-19

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

肿瘤免疫疗法下一波浪潮！联合治疗

2016-05-07

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

CHEST：言语治疗和普瑞巴林联合治疗慢性顽固性咳嗽更优

2016-03-11

科室
- - 订阅+
  - 更多科室
工具
服务